Last reviewed · How we verify
Ropeginterferon
At a glance
| Generic name | Ropeginterferon |
|---|---|
| Also known as | RoPegIFN |
| Sponsor | St. Olavs Hospital |
| Target | Interferon alpha/beta receptor |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
- Polycythemia vera
Common side effects
- Influenza-like illness
- Arthralgia
- Fatigue
- Pruritus
- Nasopharyngitis
- Musculoskeletal pain
- Liver enzyme elevations
- Leukopenia
- Thrombocytopenia
- Myalgia
Serious adverse events
- Urinary tract infection
- Transient ischemic attack
- Depression
Key clinical trials
- Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia (PHASE2)
- Ropeginterferon Alfa-2b in Patients With Polycythemia Vera (PV) Without Symptomatic Splenomegaly
- Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL) (PHASE1)
- LOW-PV Continuation
- Observational Study on the Use of Ropeginterferon Alfa-2b in Polycythemia Vera (ROPEG-PV)
- Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (PHASE2)
- Evaluation of Real-World Data on Ropeginterferon Alfa-2b in Patients With Polycythemia Vera: Insights From a Multicenter Study
- Ropeginterferon for High Risk JAK2 Clonal Hematopoiesis (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |